A study published in the Annals of Diagnostic Pathology found that the choice between MIB1 and SP6 antibodies for Ki-67 assessment in Luminal HER2-negative breast tumors led to classification discrepancies in 17 percent of cases. While both antibodies generally provided comparable proliferation indices, they influenced molecular subtyping decisions, particularly at different Ki-67 thresholds. This highlights the need for standardization in immunohistochemical scoring to improve tumor classification, necessitating further research on antibody-specific cut-offs.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
